Free Trial
NASDAQ:MYGN

Myriad Genetics (MYGN) Stock Price, News & Analysis

Myriad Genetics logo
$6.12 +0.19 (+3.12%)
As of 02:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Myriad Genetics Stock (NASDAQ:MYGN)

Key Stats

Today's Range
$5.93
$6.16
50-Day Range
$3.84
$6.32
52-Week Range
$3.76
$29.30
Volume
460,312 shs
Average Volume
1.72 million shs
Market Capitalization
$568.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.45
Consensus Rating
Hold

Company Overview

Myriad Genetics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
73rd Percentile Overall Score

MYGN MarketRank™: 

Myriad Genetics scored higher than 73% of companies evaluated by MarketBeat, and ranked 279th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Myriad Genetics has received a consensus rating of Hold. The company's average rating score is 2.21, and is based on 4 buy ratings, 9 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Myriad Genetics has received no research coverage in the past 90 days.

  • Read more about Myriad Genetics' stock forecast and price target.
  • Earnings Growth

    Earnings for Myriad Genetics are expected to remain at ($0.30) per share in the coming year.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Myriad Genetics is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Myriad Genetics is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Myriad Genetics has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Myriad Genetics' valuation and earnings.
  • Percentage of Shares Shorted

    9.36% of the float of Myriad Genetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Myriad Genetics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Myriad Genetics has recently increased by 12.43%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Myriad Genetics does not currently pay a dividend.

  • Dividend Growth

    Myriad Genetics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.36% of the float of Myriad Genetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Myriad Genetics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Myriad Genetics has recently increased by 12.43%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Myriad Genetics has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Myriad Genetics this week, compared to 8 articles on an average week.
  • Search Interest

    7 people have searched for MYGN on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Myriad Genetics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Myriad Genetics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.40% of the stock of Myriad Genetics is held by insiders.

  • Percentage Held by Institutions

    99.02% of the stock of Myriad Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Myriad Genetics' insider trading history.
Receive MYGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MYGN Stock News Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.tc pixel
Myriad Genetics reaffirms FY25 guidance
See More Headlines

MYGN Stock Analysis - Frequently Asked Questions

Myriad Genetics' stock was trading at $13.71 at the beginning of the year. Since then, MYGN stock has decreased by 55.4% and is now trading at $6.1150.

Myriad Genetics, Inc. (NASDAQ:MYGN) announced its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.03) EPS for the quarter, beating analysts' consensus estimates of ($0.05) by $0.02. The firm's revenue was down 33.6% on a year-over-year basis.
Read the conference call transcript
.

Myriad Genetics subsidiaries include Counsyl, Myriad Women’s Health, Assurex Health Inc., Myriad Neuroscience, Sividon Diagnostics, Privatklinik Dr. Robert Schindlbeck, Crescendo Bioscience, and more.

Myriad Genetics' top institutional investors include Glenview Capital Management LLC (4.93%), Geode Capital Management LLC (2.41%), Qube Research & Technologies Ltd (2.21%) and Camber Capital Management LP (2.15%). Insiders that own company stock include Paul J Diaz, Richard Bryan Riggsbee, Nicole Lambert, Heinrich Dreismann, Lee Nisley Newcomer, Colleen F Reitan and Daniel K Spiegelman.
View institutional ownership trends
.

Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Myriad Genetics investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Home Depot (HD) and Netflix (NFLX).

Company Calendar

Last Earnings
5/06/2025
Today
8/28/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MYGN
CIK
899923
Employees
2,700
Year Founded
1991

Price Target and Rating

High Price Target
$21.00
Low Price Target
$6.00
Potential Upside/Downside
+110.0%
Consensus Rating
Hold
Rating Score (0-4)
2.21
Research Coverage
14 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.28)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$127.30 million
Net Margins
-47.45%
Pretax Margin
-50.47%
Return on Equity
-5.17%
Return on Assets
-3.44%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.42
Quick Ratio
1.28

Sales & Book Value

Annual Sales
$837.60 million
Price / Sales
0.66
Cash Flow
$1.02 per share
Price / Cash Flow
5.81
Book Value
$4.17 per share
Price / Book
1.42

Miscellaneous

Outstanding Shares
93,040,000
Free Float
90,812,000
Market Cap
$551.73 million
Optionable
Optionable
Beta
1.89

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:MYGN) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners